Lisa Tanzi

Ms. Lisa Tanzi

IRBM Science Park, Pomezia, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LTLisa Tanzi
Lisa Tanzi
MTMarco Terreni
Marco Terreni
YZYongmin Zhang
Yongmin Zhang

7 December 2020 in Molecules
Verified
Journal Article
Open access
PDF file
LTLisa Tanzi
Lisa Tanzi
Marina Simona RobescuMarina Simona Robescu
Marina Simona Robescu
SMSara Marzatico
Sara Marzatico
TRTeresa Recca
Teresa Recca
YZYongmin Zhang
Yongmin Zhang
Teodora BavaroTeodora Bavaro
Teodora Bavaro
Regioselective deprotection of acetylated mannose-based mono- and disaccharides differently functionalized in anomeric position was achieved by enzymatic hydrolysis. Candida rugosa lipase (CRL) and Bacillus pumilus acetyl xylan esterase (AXE) were immobilized on octyl-Sepharose and glyoxyl-agarose, respectively. The regioselectivity of the biocatalysts was affected by the sugar structure and functionalization in anomeric position. Generally, CRL was able to catalyze regioselective deprotection of acetylated monosaccharides in C6 position. When acetylated disaccharides were used as substrates, AXE exhibited a marked preference for the C2, or C6 position when C2 was involved in the glycosidic bond. By selecting the best enzyme for each substrate in terms of activity and regioselectivity, we prepared a small library of differently monohydroxylated building blocks that could be used as intermediates for the synthesis of mannosylated glycoconjugate vaccines targeting mannose receptors of antigen presenting cells.

11 September 2020 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ZLZhihao Li
Zhihao Li
CZChangping Zheng
Changping Zheng
MTMarco Terreni
Marco Terreni
LTLisa Tanzi
Lisa Tanzi
MSMatthieu Sollogoub
Matthieu Sollogoub
YZYongmin Zhang
Yongmin Zhang
Ranking above AIDS, Tuberculosis (TB) is the ninth leading cause of death affecting and killing many individuals every year. Drugs’ efficacy is limited by a series of problems such as Multi- Drug Resistance (MDR) and Extensively-Drug Resistance (XDR). Meanwhile, the only licensed vaccine BCG (Bacillus Calmette-Guérin) existing for over 90 years is not effective enough. Consequently, it is essential to develop novel vaccines for TB prevention and immunotherapy. This paper provides an overall review of the TB prevalence, immune system response against TB and recent progress of TB vaccine research and development. Several vaccines in clinical trials are described as well as LAM-based candidates.

27 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
LTLisa Tanzi
Lisa Tanzi
Davide RubesDavide Rubes
Davide Rubes
Teodora BavaroTeodora Bavaro
Teodora Bavaro
MSMatthieu Sollogoub
Matthieu Sollogoub
Massimo SerraMassimo Serra
Massimo Serra
MTMarco Terreni
Marco Terreni
In the last few years, nanomaterials based on fullerene have begun to be considered promising tools in the development of efficient adjuvant/delivery systems for vaccination, thanks to their several advantages such as biocompatibility, size, and easy preparation and modification. In this work we reported the chemoenzymatic synthesis of natural polymannan analogues (di- and tri-mannan oligosaccharides characterized by α1,6man and/or α1,2man motifs) endowed with an anomeric propargyl group. These sugar derivatives were submitted to 1,3 Huisgen dipolar cycloaddition with a malondiamide-based chain equipped with two azido terminal groups. The obtained sugar-modified malondiamide derivatives were used to functionalize the surface of Buckminster fullerene (C60) in a highly controlled fashion, and yields (11–41%) higher than those so far reported by employing analogue linkers. The same strategy has been exploited to obtain C60 endowed with natural and unnatural amino acid derivatives. Finally, the first double functionalization of fullerene with both sugar- and amino acid-modified malondiamide chains was successfully performed, paving the way to the possible derivatization of fullerenes with immunogenic sugars and more complex antigenic peptides.